Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT
Key Takeaways
Heart failure is classified by ejection fraction into HFrEF (LVEF <=40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF >=50%).
The 4-pillar Guideline-Directed Medical Therapy (GDMT) for HFrEF consists of an ARNI (sacubitril/valsartan preferred), an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol), an MRA (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin).
A mandatory 36-hour washout period is required when transitioning a patient from an ACE inhibitor to an ARNI (sacubitril/valsartan) to prevent severe angioedema.
SGLT2 inhibitors (empagliflozin and dapagliflozin) are recommended across the entire spectrum of ejection fraction, providing proven mortality and hospitalization reductions in both HFrEF and HFpEF.
Digoxin has a narrow therapeutic range (0.5-0.9 ng/mL) and does not reduce overall mortality in heart failure; toxicity manifests with visual disturbances (yellow-green halos/xanthopsia), nausea, vomiting, confusion, and heart block.
Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT
Classification, Pathophysiology, and Neurohormonal Activation
Heart failure (HF) is classified by Left Ventricular Ejection Fraction (LVEF) on echocardiography:
- Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF <=40%. Impaired contractility (systolic dysfunction) primarily caused by ischemic heart disease or dilated cardiomyopathy.
- Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): LVEF 41% to 49%. Managed similarly to HFrEF.
- Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF >=50%. Impaired relaxation and diastolic stiffness (diastolic dysfunction) associated with aging, hypertension, obesity, metabolic syndrome, and AFib.
Progression of HFrEF is driven by chronic neurohormonal activation:
- RAAS Activation: Reduced renal perfusion stimulates renin release, raising angiotensin II and aldosterone. This causes arterial vasoconstriction, sodium/water retention, myocardial fibrosis, and LV remodeling.
- Sympathetic Overdrive: Elevated norepinephrine causes tachycardia, increased oxygen demand, cardiotoxicity, and beta-1 receptor downregulation.
- Natriuretic Peptide Breakdown: Endogenous counter-regulatory mechanisms (ANP and BNP) are overwhelmed by sustained neurohormonal stress.
Diagnostic Workup: Clinical Signs, Biomarkers, and Imaging
Diagnosis synthesizes clinical history, exam findings, biomarkers, and imaging.
Framingham Criteria: Requires 2 major criteria OR 1 major + 2 minor criteria:
- Major Criteria: Paroxysmal nocturnal dyspnea, orthopnea, jugular venous distension (JVD >4 cm), rales, cardiomegaly, acute pulmonary edema, S3 gallop, hepatojugular reflux, weight loss >4.5 kg in 5 days on diuretics.
- Minor Criteria: Ankle edema, nocturnal cough, exertional dyspnea, hepatomegaly, pleural effusion, tachycardia (HR >120 bpm).
Biomarkers: B-type Natriuretic Peptide (BNP >100 pg/mL) or NT-proBNP (>300 pg/mL) supports acute heart failure. Normal levels rule out HF.
- Clinical Pearls: Obesity lowers natriuretic peptide levels. Aging and CKD elevate levels. Patients taking an ARNI (sacubitril/valsartan) display elevated plasma BNP because sacubitril inhibits neprilysin (which degrades BNP). Therefore, NT-proBNP MUST be measured instead of BNP to evaluate patients on an ARNI.
Echocardiography: Transthoracic Echocardiography (TTE) is mandatory to quantify LVEF, chamber size, wall motion, and diastolic filling pressures (E/e' ratio).
ACC/AHA Staging System vs. NYHA Functional Classification
-
Stage A: At risk without structural heart disease (HTN, DM).
-
Stage B: Structural heart disease without HF symptoms (low EF, prior MI).
-
Stage C: Structural heart disease with prior or current HF symptoms.
-
Stage D: Refractory HF requiring advanced interventions.
-
NYHA Class I: No limitation of physical activity.
-
NYHA Class II: Slight limitation; comfortable at rest, ordinary activity causes symptoms.
-
NYHA Class III: Marked limitation; comfortable at rest, less than ordinary activity causes symptoms.
-
NYHA Class IV: Symptoms present at rest; unable to carry on any physical activity.
Recognizing that NYHA functional class fluctuates based on symptom control and treatment response whereas ACC/AHA staging only progresses forward is essential for clinical tracking.
The 4-Pillar Guideline-Directed Medical Therapy (GDMT) for HFrEF
All HFrEF patients (LVEF <=40%) should receive 4-Pillar GDMT:
| GDMT Pillar Class | Preferred Recommended Agents | Key Prescribing Rules & Monitoring Parameters |
|---|---|---|
| Pillar 1: ARNI; (or ACEi / ARB) | Sacubitril / Valsartan (ARNI); (Initial 24/26 mg or 49/51 mg BID; target 97/103 mg BID) | • Preferred over ACEi/ARB for mortality reduction.; • MANDATORY RULE: Enforce a 36-hour washout period when switching from an ACEi to ARNI to prevent severe angioedema.; • Monitor K+ and creatinine. |
| Pillar 2: Beta-Blockers | Carvedilol, Metoprolol Succinate XL, or Bisoprolol | • ONLY these 3 agents reduce mortality in HFrEF.; • Titrate slowly. Avoid in acutely decompensated HF. |
| Pillar 3: MRA | Spironolactone (12.5-25 mg) or Eplerenone (25-50 mg) | • Indicated for NYHA Class II-IV with LVEF <=40%.; • Requires K+ <5.0 mEq/L and eGFR >30 mL/min/1.73 m². |
| Pillar 4: SGLT2 Inhibitors | Dapagliflozin (10 mg) or Empagliflozin (10 mg) | • Class I recommendation for ALL HFrEF patients regardless of diabetes status.; • Reduces HF hospitalization and CV death. |
Management of HFpEF (LVEF >=50%)
SGLT2 inhibitors (Dapagliflozin 10 mg or Empagliflozin 10 mg) are a Class I recommendation for HFpEF (EMPEROR-Preserved, DELIVER), significantly reducing HF hospitalizations and CV death. Additional options in HFpEF include MRAs (spironolactone), ARNI (sacubitril/valsartan), and loop diuretics for fluid overload, combined with strict blood pressure control (<130/80 mmHg).
Symptom Control and Device Therapy
- Loop Diuretics (Furosemide, Bumetanide, Torsemide): Control congestion and restore euvolemia. Diuretics improve symptoms but do NOT reduce overall mortality.
- Device Therapy: Implantable Cardioverter-Defibrillator (ICD) is recommended for primary prevention of sudden cardiac death if LVEF <=35% despite >=3 months of optimal GDMT. Cardiac Resynchronization Therapy (CRT) is indicated for LVEF <=35%, LBBB, and QRS >=150 ms.
Geriatric Considerations & Digoxin Toxicity
Digoxin Clinical Rules: Digoxin may be added for symptomatic control in persistent NYHA Class III-IV HFrEF or AFib rate control. Digoxin does NOT reduce mortality. Therapeutic concentration window is narrow (0.5 to 0.9 ng/mL).
- Digoxin Toxicity Symptoms: Anorexia, nausea, vomiting, confusion, and visual disturbances (xanthopsia—yellow-green halos around lights). Cardiac manifestations include sinus bradycardia and AV block.
- Toxicity Triggers: Hypokalemia (potassium competes with digoxin for Na+/K+-ATPase binding; low potassium enhances digoxin binding and toxicity), hypomagnesemia, and renal decline.
Patient Education: Educate on daily morning weight checks after voiding. Patients must report weight gain of >2 to 3 lbs in 24 hours or >5 lbs in 1 week, indicating fluid retention requiring loop diuretic adjustment. Restrict sodium to <2,000 mg/day.
An APRN is preparing to transition a 65-year-old patient with HFrEF (LVEF 32%) from Lisinopril 20 mg daily to Sacubitril/Valsartan (ARNI). What critical prescribing protocol MUST be followed to minimize the risk of severe angioedema?
Administer a single intravenous dose of diphenhydramine before starting Sacubitril/Valsartan.
Enforce a mandatory 36-hour washout period after stopping Lisinopril before taking the first ARNI dose.
Overlap Lisinopril and Sacubitril/Valsartan for 5 days to prevent rebound hypertension.
No washout period is required when switching between RAAS inhibitors.
According to current ACC/AHA/HFSA heart failure guidelines, which of the following combinations represents the complete 4-Pillar Guideline-Directed Medical Therapy (GDMT) for a patient with HFrEF?
Furosemide, Lisinopril, Amlodipine, and Digoxin
Losartan, Diltiazem, Hydrochlorothiazide, and Metoprolol Tartrate
Sacubitril/Valsartan, Clonidine, Nitroglycerin, and Pravastatin
ARNI (Sacubitril/Valsartan), Evidence-based Beta-blocker, MRA (Spironolactone), and SGLT2 Inhibitor
Which class of disease-modifying heart failure medications has demonstrated significant reductions in heart failure hospitalizations and cardiovascular death across the ENTIRE spectrum of ejection fractions, making it a Class I recommendation in both HFrEF and HFpEF?
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Loop Diuretics
Non-dihydropyridine Calcium Channel Blockers
Beta-Adrenergic Blockers
An 80-year-old patient taking Digoxin 0.125 mg daily for heart failure control presents with anorexia, nausea, confusion, and reports seeing 'yellowish-green halos' around lights. Electrocardiogram reveals sinus bradycardia at 48 bpm. Which underlying lab derangement most significantly potentiates this condition?
Hypernatremia
Hypercalcemia
Hypokalemia
Hypermagnesemia
Sections you finish are checked off in the contents.